



February 2015

Tadalafil (Cialis®▼) for the treatment of symptoms associated with benign prostatic hyperplasia (BPH)

The New Therapies Subgroup discussed the above at its meeting on the 26th February 2013. The recommendation of this subgroup is as follows:*

The New Therapies Subgroup of the GMMM Group considered the use of Tadalafil 5mg once daily for the treatment of symptoms associated with benign prostatic hyperplasia (BPH).

The group does not recommend the use of tadalafil for the above indication in line with NICE TA 273.

There are other more cost effective alternatives available for this indication.

According to set criteria tadalafil for BPH was deemed to be low priority for funding.

Review date: February 2018

* Unless superseded by NICE guidance or substantial and significant new evidence becomes available.

▼ Newly marketed drugs and vaccines are intensively monitored for a minimum of two years, in order to confirm their risk / benefit profile of the product. Healthcare professionals are encouraged to report all suspected adverse drug reactions regardless of the severity of the reaction.